Genetic Inactivation of CD33 in Hematopoietic Stem Cells to Enable CAR T Cell Immunotherapy for Acute Myeloid Leukemia

Miriam Y. Kim, Kyung Rok Yu, Saad Kenderian, Marco Ruella, Shirley Chen, Tae Hoon Shin, Aisha A. Aljanahi, Daniel Schreeder, Michael Klichinsky, Olga Shestova, Miroslaw S. Kozlowski, Katherine D. Cummins, Xinhe Shan, Maksim Shestov, Adam Bagg, Jennifer J.D. Morrissette, Palak Sekhri, Cicera R. Lazzarotto, Katherine R. Calvo, Douglas B. KuhnsRobert E. Donahue, Gregory K. Behbehani, Shengdar Q. Tsai, Cynthia E. Dunbar, Saar Gill

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

The absence of cancer-restricted surface markers is a major impediment to antigen-specific immunotherapy using chimeric antigen receptor (CAR) T cells. For example, targeting the canonical myeloid marker CD33 in acute myeloid leukemia (AML) results in toxicity from destruction of normal myeloid cells. We hypothesized that a leukemia-specific antigen could be created by deleting CD33 from normal hematopoietic stem and progenitor cells (HSPCs), thereby generating a hematopoietic system resistant to CD33-targeted therapy and enabling specific targeting of AML with CAR T cells. We generated CD33-deficient human HSPCs and demonstrated normal engraftment and differentiation in immunodeficient mice. Autologous CD33 KO HSPC transplantation in rhesus macaques demonstrated long-term multilineage engraftment of gene-edited cells with normal myeloid function. CD33-deficient cells were impervious to CD33-targeting CAR T cells, allowing for efficient elimination of leukemia without myelotoxicity. These studies illuminate a novel approach to antigen-specific immunotherapy by genetically engineering the host to avoid on-target, off-tumor toxicity. Reconstitution of the immune system with CD33-negative human hematopoietic stem cells enables anti-CD33 CAR-T cell killing of acute myeloid leukemia while sparing myeloid development and function.

Original languageEnglish (US)
Pages (from-to)1439-1453.e19
JournalCell
Volume173
Issue number6
DOIs
StatePublished - May 31 2018

Fingerprint

Hematopoietic Stem Cells
T-Cell Antigen Receptor
Stem cells
Acute Myeloid Leukemia
Immunotherapy
Antigens
Toxicity
Immune system
Sialic Acid Binding Ig-like Lectin 3
Leukemia
Hematopoietic System
Tumors
Antigen Receptors
Genes
Hematopoietic Stem Cell Transplantation
Myeloid Cells
Macaca mulatta
Immune System
Neoplasms
T-Lymphocytes

Keywords

  • acute myeloid leukemia
  • CD33
  • chimeric antigen receptor T cells
  • CRISPR/Cas9 gene editing
  • hematopoiesis
  • immunotherapy
  • non-human primate hematopoiesis

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Genetic Inactivation of CD33 in Hematopoietic Stem Cells to Enable CAR T Cell Immunotherapy for Acute Myeloid Leukemia. / Kim, Miriam Y.; Yu, Kyung Rok; Kenderian, Saad; Ruella, Marco; Chen, Shirley; Shin, Tae Hoon; Aljanahi, Aisha A.; Schreeder, Daniel; Klichinsky, Michael; Shestova, Olga; Kozlowski, Miroslaw S.; Cummins, Katherine D.; Shan, Xinhe; Shestov, Maksim; Bagg, Adam; Morrissette, Jennifer J.D.; Sekhri, Palak; Lazzarotto, Cicera R.; Calvo, Katherine R.; Kuhns, Douglas B.; Donahue, Robert E.; Behbehani, Gregory K.; Tsai, Shengdar Q.; Dunbar, Cynthia E.; Gill, Saar.

In: Cell, Vol. 173, No. 6, 31.05.2018, p. 1439-1453.e19.

Research output: Contribution to journalArticle

Kim, MY, Yu, KR, Kenderian, S, Ruella, M, Chen, S, Shin, TH, Aljanahi, AA, Schreeder, D, Klichinsky, M, Shestova, O, Kozlowski, MS, Cummins, KD, Shan, X, Shestov, M, Bagg, A, Morrissette, JJD, Sekhri, P, Lazzarotto, CR, Calvo, KR, Kuhns, DB, Donahue, RE, Behbehani, GK, Tsai, SQ, Dunbar, CE & Gill, S 2018, 'Genetic Inactivation of CD33 in Hematopoietic Stem Cells to Enable CAR T Cell Immunotherapy for Acute Myeloid Leukemia', Cell, vol. 173, no. 6, pp. 1439-1453.e19. https://doi.org/10.1016/j.cell.2018.05.013
Kim, Miriam Y. ; Yu, Kyung Rok ; Kenderian, Saad ; Ruella, Marco ; Chen, Shirley ; Shin, Tae Hoon ; Aljanahi, Aisha A. ; Schreeder, Daniel ; Klichinsky, Michael ; Shestova, Olga ; Kozlowski, Miroslaw S. ; Cummins, Katherine D. ; Shan, Xinhe ; Shestov, Maksim ; Bagg, Adam ; Morrissette, Jennifer J.D. ; Sekhri, Palak ; Lazzarotto, Cicera R. ; Calvo, Katherine R. ; Kuhns, Douglas B. ; Donahue, Robert E. ; Behbehani, Gregory K. ; Tsai, Shengdar Q. ; Dunbar, Cynthia E. ; Gill, Saar. / Genetic Inactivation of CD33 in Hematopoietic Stem Cells to Enable CAR T Cell Immunotherapy for Acute Myeloid Leukemia. In: Cell. 2018 ; Vol. 173, No. 6. pp. 1439-1453.e19.
@article{0c9dcfbff1d14850a43e49d56f7be3d8,
title = "Genetic Inactivation of CD33 in Hematopoietic Stem Cells to Enable CAR T Cell Immunotherapy for Acute Myeloid Leukemia",
abstract = "The absence of cancer-restricted surface markers is a major impediment to antigen-specific immunotherapy using chimeric antigen receptor (CAR) T cells. For example, targeting the canonical myeloid marker CD33 in acute myeloid leukemia (AML) results in toxicity from destruction of normal myeloid cells. We hypothesized that a leukemia-specific antigen could be created by deleting CD33 from normal hematopoietic stem and progenitor cells (HSPCs), thereby generating a hematopoietic system resistant to CD33-targeted therapy and enabling specific targeting of AML with CAR T cells. We generated CD33-deficient human HSPCs and demonstrated normal engraftment and differentiation in immunodeficient mice. Autologous CD33 KO HSPC transplantation in rhesus macaques demonstrated long-term multilineage engraftment of gene-edited cells with normal myeloid function. CD33-deficient cells were impervious to CD33-targeting CAR T cells, allowing for efficient elimination of leukemia without myelotoxicity. These studies illuminate a novel approach to antigen-specific immunotherapy by genetically engineering the host to avoid on-target, off-tumor toxicity. Reconstitution of the immune system with CD33-negative human hematopoietic stem cells enables anti-CD33 CAR-T cell killing of acute myeloid leukemia while sparing myeloid development and function.",
keywords = "acute myeloid leukemia, CD33, chimeric antigen receptor T cells, CRISPR/Cas9 gene editing, hematopoiesis, immunotherapy, non-human primate hematopoiesis",
author = "Kim, {Miriam Y.} and Yu, {Kyung Rok} and Saad Kenderian and Marco Ruella and Shirley Chen and Shin, {Tae Hoon} and Aljanahi, {Aisha A.} and Daniel Schreeder and Michael Klichinsky and Olga Shestova and Kozlowski, {Miroslaw S.} and Cummins, {Katherine D.} and Xinhe Shan and Maksim Shestov and Adam Bagg and Morrissette, {Jennifer J.D.} and Palak Sekhri and Lazzarotto, {Cicera R.} and Calvo, {Katherine R.} and Kuhns, {Douglas B.} and Donahue, {Robert E.} and Behbehani, {Gregory K.} and Tsai, {Shengdar Q.} and Dunbar, {Cynthia E.} and Saar Gill",
year = "2018",
month = "5",
day = "31",
doi = "10.1016/j.cell.2018.05.013",
language = "English (US)",
volume = "173",
pages = "1439--1453.e19",
journal = "Cell",
issn = "0092-8674",
publisher = "Cell Press",
number = "6",

}

TY - JOUR

T1 - Genetic Inactivation of CD33 in Hematopoietic Stem Cells to Enable CAR T Cell Immunotherapy for Acute Myeloid Leukemia

AU - Kim, Miriam Y.

AU - Yu, Kyung Rok

AU - Kenderian, Saad

AU - Ruella, Marco

AU - Chen, Shirley

AU - Shin, Tae Hoon

AU - Aljanahi, Aisha A.

AU - Schreeder, Daniel

AU - Klichinsky, Michael

AU - Shestova, Olga

AU - Kozlowski, Miroslaw S.

AU - Cummins, Katherine D.

AU - Shan, Xinhe

AU - Shestov, Maksim

AU - Bagg, Adam

AU - Morrissette, Jennifer J.D.

AU - Sekhri, Palak

AU - Lazzarotto, Cicera R.

AU - Calvo, Katherine R.

AU - Kuhns, Douglas B.

AU - Donahue, Robert E.

AU - Behbehani, Gregory K.

AU - Tsai, Shengdar Q.

AU - Dunbar, Cynthia E.

AU - Gill, Saar

PY - 2018/5/31

Y1 - 2018/5/31

N2 - The absence of cancer-restricted surface markers is a major impediment to antigen-specific immunotherapy using chimeric antigen receptor (CAR) T cells. For example, targeting the canonical myeloid marker CD33 in acute myeloid leukemia (AML) results in toxicity from destruction of normal myeloid cells. We hypothesized that a leukemia-specific antigen could be created by deleting CD33 from normal hematopoietic stem and progenitor cells (HSPCs), thereby generating a hematopoietic system resistant to CD33-targeted therapy and enabling specific targeting of AML with CAR T cells. We generated CD33-deficient human HSPCs and demonstrated normal engraftment and differentiation in immunodeficient mice. Autologous CD33 KO HSPC transplantation in rhesus macaques demonstrated long-term multilineage engraftment of gene-edited cells with normal myeloid function. CD33-deficient cells were impervious to CD33-targeting CAR T cells, allowing for efficient elimination of leukemia without myelotoxicity. These studies illuminate a novel approach to antigen-specific immunotherapy by genetically engineering the host to avoid on-target, off-tumor toxicity. Reconstitution of the immune system with CD33-negative human hematopoietic stem cells enables anti-CD33 CAR-T cell killing of acute myeloid leukemia while sparing myeloid development and function.

AB - The absence of cancer-restricted surface markers is a major impediment to antigen-specific immunotherapy using chimeric antigen receptor (CAR) T cells. For example, targeting the canonical myeloid marker CD33 in acute myeloid leukemia (AML) results in toxicity from destruction of normal myeloid cells. We hypothesized that a leukemia-specific antigen could be created by deleting CD33 from normal hematopoietic stem and progenitor cells (HSPCs), thereby generating a hematopoietic system resistant to CD33-targeted therapy and enabling specific targeting of AML with CAR T cells. We generated CD33-deficient human HSPCs and demonstrated normal engraftment and differentiation in immunodeficient mice. Autologous CD33 KO HSPC transplantation in rhesus macaques demonstrated long-term multilineage engraftment of gene-edited cells with normal myeloid function. CD33-deficient cells were impervious to CD33-targeting CAR T cells, allowing for efficient elimination of leukemia without myelotoxicity. These studies illuminate a novel approach to antigen-specific immunotherapy by genetically engineering the host to avoid on-target, off-tumor toxicity. Reconstitution of the immune system with CD33-negative human hematopoietic stem cells enables anti-CD33 CAR-T cell killing of acute myeloid leukemia while sparing myeloid development and function.

KW - acute myeloid leukemia

KW - CD33

KW - chimeric antigen receptor T cells

KW - CRISPR/Cas9 gene editing

KW - hematopoiesis

KW - immunotherapy

KW - non-human primate hematopoiesis

UR - http://www.scopus.com/inward/record.url?scp=85047396504&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85047396504&partnerID=8YFLogxK

U2 - 10.1016/j.cell.2018.05.013

DO - 10.1016/j.cell.2018.05.013

M3 - Article

C2 - 29856956

AN - SCOPUS:85047396504

VL - 173

SP - 1439-1453.e19

JO - Cell

JF - Cell

SN - 0092-8674

IS - 6

ER -